Bristol Myers Squibb reported $5.39B in Pre-Tax Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Abbott ABT:US $ 3899M 1051M
Abbvie ABBV:US $ 6567M 197M
Amgen AMGN:US $ 2727M 56M
Astrazeneca AZN:US $ 3709M 624M
Biogen BIIB:US $ 903.4M 316.6M
Bristol Myers Squibb BMY:US $ 5386M 595M
Catalent CTLT:US $ 251M 37M
Coherus Biosciences CHRS:US $ -96.08M 50.36M
Intercept Pharmaceuticals ICPT:US $ -17.28M 19M
JAZZ PHA JAZZ:US $ 321.29M 19.04M
Johnson & Johnson JNJ:US $ 8218M 1879M
Medtronic MDT:US $ 2345M 233M
Merk MRK:US $ 6309M 1525M
Novartis NOVN:VX SF 3912M 230M
Pfizer PFE:US $ 11328M 4083M
Regeneron Pharmaceuticals REGN:US $ 1119.1M 1986M
Revance Therapeutics RVNC:US $ -64.34M 1.24M
Sanofi SAN:FP € 2965M 804M
Teva Pharmaceutical Industries TEVA:US $ 766M 253M
United Therapeutics UTHR:US $ 308.7M 168.2M
Zoetis ZTS:US $ 769M 188M